Buzzing Stocks Today: Lupin, Zee, Sun Pharma, NTPC, PCBL, Care Ratings

Stocks to Keep an Eye on Monday, December 18, 2023: Following a frenzied run at the close of the previous week, equity markets are set to begin the new week on a more subdued note. Furthermore, the benchmark indexes have risen by more than 13% in the previous seven weeks.

Gift Nifty futures were quoted at 21,470 at 06:30 AM, predicting a flat to modestly bearish opening for the Nifty 50. 

Read More: Aishwarya Rai’s Net Worth Gone Viral Following Divorce Rumors

Meanwhile, these are the stocks that will most likely be watched on Monday. 

Zee Entertainment: 

As the proposed merger with Sony India approached the December 21 deadline, the media conglomerate sought an extension on Sunday. While the merger of the two firms was approved, disagreements have arisen about who would serve as the merged entity’s chief executive officer (CEO).

Lupin and Sun Pharma: 

According to the US Food and Drug Administration (USFDA), the two pharmaceutical companies are recalling medicines in the US market due to production concerns. Sun Pharma is recalling 96,192 bottles of Liothyronine Sodium pills in the United States, while Lupin is recalling an undefined amount of penicillamine pills.

SBI: 

The largest lender in India has reduced unsecured retail loans in order to focus on ‘healthy’ growth, even if overall loan growth is likely to remain robust at 15% in FY24 due to consistent demand from corporates, according to chairman Dinesh Khara.

Bata India: 

According to its new strategy, the footwear business has signed a license arrangement with Nine West, under which Bata will produce and distribute its footwear and accessories (handbags) in India. Furthermore, is promoting its Floatz product line in order to capture a part of the molded footwear industry at a cheaper price than Crocs and Birkenstock. 

NTPC: 

Plans to expand the Sipat Super Thermal Power Station in Chhattisgarh’s Bilaspur district by 800 megawatts (MW).

Care Scores: 

Sebi issued a warning for several irregularities discovered during an investigation between December 2021 and April 2023. Within 30 days, the organization must take corrective action, resolve any anomalies, and submit the action taken report (ATR).